Ironwood Pharmaceuticals (formerly Microbia) is a drug developer that is busy testing the gastrointestinal drug candidates in its pipeline. The company is developing lead drug candidate linaclotide, which is undergoing trials in partnership with Forest Laboratories and other co-developers for the treatment of irritable bowel syndrome, abdominal pain, and chronic constipation. The company's Microbia biotechnology subsidiary harnesses microbes to produce specialty chemicals from renewable resources with applications the agriculture, chemical, and pharmaceutical industries. Ironwood Pharmaceuticals made a move to go public when it filed for an IPO in 2009.

The revolution in genomics and proteomics spawned by the human genome project is providing a steady stream of protein therapeutic candidates. Many of these proteins require enhancements in their pharmacokinetic properties in order to be clinically effective because of inherent limitations of proteins as drugs. Advanced Proteome Therapeutics has initiated a program that is broadly applicable to proteins. It builds on a technology platform developed over twenty years of targeting proteins for site-selective modification and addresses issues which limit therapeutic utilization of promising proteins.The Company’s laboratories are located at the BioSquare Innovation and Discovery Center on the campus of the Boston University School of Medicine. Its scientists are engaged in research and development applying leading edge chemical and biochemical methodologies to commercially viable proteins. The technology is applicable to the generation of a variety of protein products including protein therapeutics, protein diagnostics and high value reagents for research.

Laureate Pharma's protein purification and other production processes are pure poetry in motion. The contract manufacturing organization (CMO) develops, manufactures, and packages products used by pharmaceutical and biopharmaceutical companies to make drugs and diagnostics. The company's biopharmaceutical division specializes in making monoclonal antibodies and provides protein production and purification. Laureate also provides product formulation, aseptic filling, and bulk processing. It has partnerships with EMD Chemicals and GTC Biotherapeutics to provide products for clinical trials. Investment firm Safeguard Scientifics has sold its majority stake in Laureate Pharma to Saints Capital.

Centocor Ortho Biotech has ways of making your immune system behave itself. The Johnson & Johnson subsidiary makes blockbuster biotech drug Remicade, a monoclonal antibody used to treat a number of autoimmune conditions, or diseases in which the body's immune system attacks its own tissues. It is approved in the US and Europe for several indications, including Crohn's disease, ulcerative colitis, psoriasis, rheumatoid arthritis, and ankylosing spondylitis (a type of arthritis of the spine). The company also makes oncology drugs Doxil and Leustatin, and immunosuppressant Orthoclone for organ transplantation.

Laboratorio Chile S.A. makes branded, generic, and OTC drugs, including treatments for respiratory and infectious diseases, as well as cardiovascular, neurological, pain management, and hormone therapy products. Laboratorio Chile also makes such consumer fare as sweetener Marco Sweet, nutritional supplement Esvit-C, and Freshmel antiseptic throat lozenges. The company markets its wares in over a dozen Latin American countries.

Sinclair Pharma can help those with itchy skin or bleeding gums. The specialty pharmaceutical development company acquires oral health and dermatology companies that have already begun developing products and turns them into new lines or line extensions for commercial sale. Its top sellers include Aloclair for mouth ulcers, Decapinol for gingivitis, and Atopiclair for ezcema. It has a sales presence in the UK, France, Italy, Portugal, and Spain, with marketing partners in more than 80 countries. When former CEO Michael Flynn led a management buy-in in 2000, Sinclair's strategy shifted from being a traditional early research and development company to an acquisition vehicle of late-stage development products.

Intervet/Schering-Plough Animal Health company develops, manufactures, and markets veterinary vaccines and pharmaceutical products. Its product portfolio includes vaccines for use in pets, livestock, poultry and aquaculture; treatment lines include antiparasitics, anti-infectives, and endocrine products. Intervet/Schering-Plough Animal Health also develops feed additives and animal productivity enhancers. Intervet/Schering-Plough Animal Health operates in more than 50 countries and sells its products around the world. Intervet/Schering-Plough Animal Health company is a subsidiary of Merck.

Schiff Nutrition International, Inc. was founded in 1996 and is headquartered in Salt Lake City, Utah. Schiff Nutrition International, Inc. develops, manufactures, markets and distributes branded and private label vitamins, nutritional supplements and nutrition bars in the United States and throughout the world. The Company offers a range of capsules, tablets and nutrition bars. Its portfolio of brands includes Schiff, Move Free, MegaRed and Tiger’s Milk, which is marketed through the mass market, including club and health food store distribution channels. The Company markets a range of specialty supplements, vitamins and minerals under the Schiff brand. The Schiff brand specialty supplements are designed to provide consumers with targeted support for their wellness efforts. Its specialty supplements include joint care products marketed under the Schiff brand, including its Move Free and Glucosamine products. Its Move Free product is one of the joint care products in the mass market channel.

YM Biosciences was founded in 1994 and is headquartered in Mississauga, Canada. YM Biosciences Inc., a biopharmaceutical company, engages in the licensing and commercialization of drug products and technologies primarily for the treatment of cancer or cancer-related conditions worldwide. Its approved product Nimotuzumab, a humanized monoclonal antibody that targets the epidermal growth factor receptor, is used for the treatment nasopharyngeal carcinomas, head and neck cancer, refractory children glioma, adult glioma, and stage III/IV glioma. The company is also developing Nimotuzumab for various other epithelial cancers; and AeroLEF, a proprietary formulation of free and liposome-encapsulated fentanyl administered by pulmonary inhalation for the treatment of severe and moderate acute pain, including cancer pain. In addition, its other product candidates include TGFa and HER-1, the anti-cancer vaccines.

Biodel Inc. company was founded in 2003 and is headquartered in Danbury, Connecticut. Biodel Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of treatments for diabetes. The company develops its product candidates by utilizing its proprietary VIAdel technology that allows to study the interaction between peptide hormones and small molecules. Its product candidates include VIAject, an injectable formulation of recombinant human insulin, which has completed two pivotal Phase III clinical trials for the treatment of Type 1 and Type 2 diabetes; and VIAtab, a sublingual tablet formulation of insulin, which has completed Phase I clinical trial for Type 1 diabetes.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.